Document is current
Any future updates will be listed below
-
Authors
Maretty, Lasse
Gill, Dipender https://orcid.org/0000-0001-7312-7078
Simonsen, Lotte https://orcid.org/0000-0001-6914-0069
Soh, Keng
Zagkos, Loukas https://orcid.org/0000-0002-7700-8102
Galanakis, Michael
Sibbesen, Jonas
Iglesias, Miquel Triana https://orcid.org/0000-0003-2161-8355
Secher, Anna https://orcid.org/0000-0002-6276-5389
Valkenborg, Dirk
Purnell, Jonathan Q. https://orcid.org/0000-0001-5505-6333
Knudsen, Lotte Bjerre https://orcid.org/0000-0002-2439-7116
Tahrani, Abd A. https://orcid.org/0000-0001-9037-1937
Geybels, Milan
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S
- License Information
-
More Information
Article History
Received: 22 March 2024
Accepted: 14 October 2024
First Online: 3 January 2025
Competing interests
: L.S., K.S., M. Galanakis, M.T.I., J.S., A.S., L.B.K. and A.A.T. are employees and shareholders of Novo Nordisk. D.G., L.M. and M. Geybels were employees and shareholders of Novo Nordisk at the time of the analysis. M. Galanakis, M. Geybels and D.V. have received a grant from the Danish Innovation Fund (204000005B). J.Q.P. has received consulting fees from Boehringer Ingelheim and Novo Nordisk. L.Z. declares no competing interests.
